GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » Cash-to-Debt

Vaxart (Vaxart) Cash-to-Debt : 1.98 (As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Vaxart Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vaxart's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.98.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vaxart could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Vaxart's Cash-to-Debt or its related term are showing as below:

VXRT' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.98   Med: 15.2   Max: No Debt
Current: 1.98

During the past 13 years, Vaxart's highest Cash to Debt Ratio was No Debt. The lowest was 1.98. And the median was 15.20.

VXRT's Cash-to-Debt is ranked worse than
68.12% of 1537 companies
in the Biotechnology industry
Industry Median: 6.49 vs VXRT: 1.98

Vaxart Cash-to-Debt Historical Data

The historical data trend for Vaxart's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vaxart Cash-to-Debt Chart

Vaxart Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.85 17.60 12.80 4.41 1.98

Vaxart Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.41 3.34 3.23 2.55 1.98

Competitive Comparison of Vaxart's Cash-to-Debt

For the Biotechnology subindustry, Vaxart's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vaxart's Cash-to-Debt falls into.



Vaxart Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vaxart's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Vaxart's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxart  (NAS:VXRT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Vaxart Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vaxart's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxart (Vaxart) Business Description

Traded in Other Exchanges
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Executives
W. Mark Watson director 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Phillip E Lee officer: Chief Financial Officer C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Elaine J Heron director 6 STONEGATE RD, PONTOLA VALLEY CA 94028
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Edward B Berg officer: SVP, General Counsel C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Robert A. Yedid director C/O LIFESCI ADVISORS, 250 WEST 55TH STREET, SUITE 3401, NEW YORK NY 10019
Margaret Echerd officer: VP, Corporate Controller, PAO 3585 MONROE STREET, SANTA CLARA CA 95051
James F. Cummings officer: Chief Medical Officer 1312 BEACHVIEW ROAD, ANNAPOLIS MD 21403
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Sean Tucker officer: Chief Scientific Officer 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
Wouter Latour director, officer: President and Chief Executive 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037